A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice

Nutrients

Volumn 10, Issue 2, 2018, Pages

  Nakamura, Kentaro ^a   Tonouchi, Hidekazu ^a   Sasayama, Akina ^a   Ashida, Kinya ^a  

^a NHK SCIENCE AND TECHNICAL RESEARCH LABORATORIES   (Japan)

Author keywords

Cancer cachexia; Colorectal cancer; Inflammation; Ketogenic formula; Ketone body

Indexed keywords

3 HYDROXYBUTYRIC ACID; CARBOHYDRATE; CYTOKINE; INTERLEUKIN 6; PROSTAGLANDIN E2; INTERLEUKIN-6, MOUSE; KETONE BODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CACHEXIA; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESISTANT EPILEPSY; INFLAMMATION; KETOGENIC DIET; MALE; MOUSE; MUSCLE MASS; NONHUMAN; TUMOR GROWTH; TUMOR WEIGHT; ADENOCARCINOMA; ANIMAL; BLOOD; BODY WEIGHT LOSS; CALORIC INTAKE; CANCER TRANSPLANTATION; COLORECTAL TUMOR; DIET THERAPY; IMMUNOLOGY; OBESITY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; REPRODUCIBILITY; SKELETAL MUSCLE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR CELL LINE; TUMOR VOLUME;

ADENOCARCINOMA; ADIPOSITY; ANIMALS; CACHEXIA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIET, KETOGENIC; ENERGY INTAKE; INTERLEUKIN-6; KETONE BODIES; MALE; MICE; MUSCLE, SKELETAL; NEOPLASM TRANSPLANTATION; ORGAN SIZE; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR BURDEN; WEIGHT LOSS;

EID: 85042085185     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10020206     Document Type: Article

References (37)

1. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011, 12, 489–495. [CrossRef]
2. Prado, C.M.; Lieffers, J.R.; McCargar, L.J.; Reiman, T.; Sawyer, M.B.; Martin, L.; Baracos, V.E. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 2008, 9, 629–635. [CrossRef]
3. Nakamura, K.; Sasayama, A.; Takahashi, T.; Yamaji, T. An immune-modulating diet in combination with chemotherapy prevents cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutr. Cancer 2015, 67, 912–920. [CrossRef] [PubMed]
4. Fearon, K. Cancer cachexia: Developing multimodal therapy for a multidimensional problem. Eur. J. Cancer 2008, 44, 1124–1132. [CrossRef] [PubMed]
5. Seyfried, T.N.; Flores, R.E.; Poff, A.M.; D’Agostino, D.P. Cancer as a metabolic disease: Implications for novel therapeutics. Carcinogenesis 2014, 35. [CrossRef] [PubMed]
6. Allen, B.G.; Bhatia, S.K.; Anderson, C.M.; Eichenberger-Gilmore, J.M.; Sibenaller, Z.A.; Mapuskar, K.A.; Schoenfeld, J.D.; Buatti, J.M.; Spitz, D.R.; Fath, M.A. Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox Biol. 2014, 2, 963–970. [CrossRef] [PubMed]
7. Vidali, S.; Aminzadeh, S.; Lambert, B.; Rutherford, T.; Sperl, W.; Kofler, B.; Feichtinger, R.G. Mitochondria: The ketogenic diet—A metabolism-based therapy. Int. J. Biochem. Cell Biol. 2015, 63, 55–59. [CrossRef] [PubMed]
8. Gasior, M.; Rogawski, M.A.; Hartman, A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 2006, 17, 431–439. [CrossRef] [PubMed]
9. Hayashi, A.; Kumada, T.; Nozaki, F.; Hiejima, I.; Miyajima, T.; Fujii, T. Changes in serum levels of selenium, zinc and copper in patients on a ketogenic diet using ketonformula. No To Hattatsu 2013, 45, 288–293. [PubMed]
10. Seyfried, T.N.; Shelton, L.M. Cancer as a metabolic disease. Nutr. Metab. 2010, 7, 7. [CrossRef] [PubMed]
11. Klement, R.J.; Champ, C.E.; Otto, C.; Kammerer, U. Anti-tumor effects of ketogenic diets in mice: A meta-analysis. PLoS ONE 2016, 11, e0155050. [CrossRef] [PubMed]
12. Lv, M.; Zhu, X.; Wang, H.; Wang, F.; Guan, W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: A systematic review and meta-analysis. PLoS ONE 2014, 9, e115147. [CrossRef] [PubMed]
13. Wheatley, K.E.; Williams, E.A.; Smith, N.C.; Dillard, A.; Park, E.Y.; Nunez, N.P.; Hursting, S.D.; Lane, M.A. Low-carbohydrate diet versus caloric restriction: Effects on weight loss, hormones, and colon tumor growth in obese mice. Nutr. Cancer 2008, 60, 61–68. [CrossRef] [PubMed]
14. Zhou, W.; Mukherjee, P.; Kiebish, M.A.; Markis, W.T.; Mantis, J.G.; Seyfried, T.N. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr. Metab. 2007, 4. [CrossRef] [PubMed]
15. Bielohuby, M.; Menhofer, D.; Kirchner, H.; Stoehr, B.J.; Muller, T.D.; Stock, P.; Hempel, M.; Stemmer, K.; Pfluger, P.T.; Kienzle, E.; et al. Induction of ketosis in rats fed low-carbohydrate, high-fat diets depends on the relative abundance of dietary fat and protein. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E65–E76. [CrossRef] [PubMed]
16. Kennedy, A.R.; Pissios, P.; Otu, H.; Roberson, R.; Xue, B.; Asakura, K.; Furukawa, N.; Marino, F.E.; Liu, F.F.; Kahn, B.B.; et al. A high-fat, ketogenic diet induces a unique metabolic state in mice. Am. J. Physiol. Endocrinol. Metab. 2007, 292, E1724–E1739. [CrossRef] [PubMed]
17. Deans, C.; Wigmore, S.J. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8, 265–269. [CrossRef] [PubMed]
18. Tisdale, M.J. Mechanisms of cancer cachexia. Physiol. Rev. 2009, 89, 381–410. [CrossRef] [PubMed]
19. Fu, S.P.; Wang, J.F.; Xue, W.J.; Liu, H.M.; Liu, B.R.; Zeng, Y.L.; Li, S.N.; Huang, B.X.; Lv, Q.K.; Wang, W.; et al. Anti-inflammatory effects of BHBA in both in vivo and in vitro parkinson's disease models are mediated by GPR109A-dependent mechanisms. J. Neuroinflamm. 2015, 12, 9. [CrossRef] [PubMed]
20. Youm, Y.H.; Nguyen, K.Y.; Grant, R.W.; Goldberg, E.L.; Bodogai, M.; Kim, D.; D'Agostino, D.; Planavsky, N.; Lupfer, C.; Kanneganti, T.D.; et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 2015, 21, 263–269. [CrossRef] [PubMed]
21. Fine, E.J.; Segal-Isaacson, C.J.; Feinman, R.D.; Herszkopf, S.; Romano, M.C.; Tomuta, N. Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients. Nutrition 2012, 28. [CrossRef] [PubMed]
22. Pi-Sunyer, F.X.; Hashim, S.A.; Van Itallie, T.B. Insulin and ketone responses to ingestion of medium and long-chain triglycerides in man. Diabetes 1969, 18, 96–100. [CrossRef] [PubMed]
23. Beck, S.A.; Tisdale, M.J. Effect of insulin on weight loss and tumour growth in a cachexia model. Br. J. Cancer 1989, 59, 677–681. [CrossRef] [PubMed]
24. Beck, S.A.; Tisdale, M.J. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Res. 1989, 49, 3800–3804. [PubMed]
25. Nishi, Y.; Hiejima, H.; Hosoda, H.; Kaiya, H.; Mori, K.; Fukue, Y.; Yanase, T.; Nawata, H.; Kangawa, K.; Kojima, M. Ingested medium-chain fatty acids are directly utilized for the acyl modification of ghrelin. Endocrinology 2005, 146, 2255–2264. [CrossRef] [PubMed]
26. Ashitani, J.; Matsumoto, N.; Nakazato, M. Effect of octanoic acid-rich formula on plasma ghrelin levels in cachectic patients with chronic respiratory disease. Nutr. J. 2009, 8, 25. [CrossRef] [PubMed]
27. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402, 656–660. [CrossRef] [PubMed]
28. Tanaka, Y.; Eda, H.; Tanaka, T.; Udagawa, T.; Ishikawa, T.; Horii, I.; Ishitsuka, H.; Kataoka, T.; Taguchi, T. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 1990, 50, 2290–2295. [PubMed]
29. Recinella, L.; Leone, S.; Ferrante, C.; Chiavaroli, A.; Di Nisio, C.; Martinotti, S.; Vacca, M.; Brunetti, L.; Orlando, G. Effects of central fibroblast growth factor 21 (FGF21) in energy balance. J. Biol. Regul. Homeost. Agents 2017, 31, 603–613. [PubMed]
30. Stemmer, K.; Zani, F.; Habegger, K.M.; Neff, C.; Kotzbeck, P.; Bauer, M.; Yalamanchilli, S.; Azad, A.; Lehti, M.; Martins, P.J.; et al. FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice. Diabetologia 2015, 58, 2414–2423. [CrossRef] [PubMed]
31. Murata, Y.; Nishio, K.; Mochiyama, T.; Konishi, M.; Shimada, M.; Ohta, H.; Itoh, N. FGF21 impairs adipocyte insulin sensitivity in mice fed a low-carbohydrate, high-fat ketogenic diet. PLoS ONE 2013, 8, e69330. [CrossRef] [PubMed]
32. Zuccoli, G.; Marcello, N.; Pisanello, A.; Servadei, F.; Vaccaro, S.; Mukherjee, P.; Seyfried, T.N. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case report. Nutr. Metab. 2010, 7, 33. [CrossRef] [PubMed]
33. Schmidt, M.; Pfetzer, N.; Schwab, M.; Strauss, I.; Kammerer, U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr. Metab. 2011, 8, 54. [CrossRef] [PubMed]
34. Rieger, J.; Bahr, O.; Maurer, G.D.; Hattingen, E.; Franz, K.; Brucker, D.; Walenta, S.; Kammerer, U.; Coy, J.F.; Weller, M.; et al. Ergo: A pilot study of ketogenic diet in recurrent glioblastoma. Int. J. Oncol. 2014, 44, 1843–1852. [CrossRef] [PubMed]
35. Hirano, Y.; Oguni, H.; Shiota, M.; Nishikawa, A.; Osawa, M. Ketogenic diet therapy can improve acth-resistant west syndrome in Japan. Brain Dev. 2015, 37, 18–22. [CrossRef] [PubMed]
36. Ravasco, P.; Monteiro-Grillo, I.; Vidal, P.M.; Camilo, M.E. Cancer: Disease and nutrition are key determinants of patients' quality of life. Support. Care Cancer 2004, 12, 246–252. [CrossRef] [PubMed]
37. Daenen, L.G.; Cirkel, G.A.; Houthuijzen, J.M.; Gerrits, J.; Oosterom, I.; Roodhart, J.M.; van Tinteren, H.; Ishihara, K.; Huitema, A.D.; Verhoeven-Duif, N.M.; et al. Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncol. 2015, 1, 350–358. [CrossRef] [PubMed]